CA2065346C - Recepteurs .alpha. et .beta. de facteur de necrose tumorale - Google Patents

Recepteurs .alpha. et .beta. de facteur de necrose tumorale Download PDF

Info

Publication number
CA2065346C
CA2065346C CA002065346A CA2065346A CA2065346C CA 2065346 C CA2065346 C CA 2065346C CA 002065346 A CA002065346 A CA 002065346A CA 2065346 A CA2065346 A CA 2065346A CA 2065346 C CA2065346 C CA 2065346C
Authority
CA
Canada
Prior art keywords
amino acids
protein
sequence
tnf
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002065346A
Other languages
English (en)
Other versions
CA2065346A1 (fr
Inventor
Craig A. Smith
Raymond G. Goodwin
M. Patricia Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority to CA002485553A priority Critical patent/CA2485553A1/fr
Publication of CA2065346A1 publication Critical patent/CA2065346A1/fr
Application granted granted Critical
Publication of CA2065346C publication Critical patent/CA2065346C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002065346A 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale Expired - Lifetime CA2065346C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002485553A CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40324189A 1989-09-05 1989-09-05
US403,241 1989-09-05
US40537089A 1989-09-11 1989-09-11
US405,370 1989-09-11
US42141789A 1989-10-13 1989-10-13
US421,417 1989-10-13
PCT/US1990/004001 WO1991003553A1 (fr) 1989-09-05 1990-07-17 RECEPTEURS DES FACTEURS NECROSE TUMORALE α et $g(b)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002485553A Division CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Publications (2)

Publication Number Publication Date
CA2065346A1 CA2065346A1 (fr) 1991-03-06
CA2065346C true CA2065346C (fr) 2005-03-29

Family

ID=46201946

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002485553A Expired - Lifetime CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale
CA002065346A Expired - Lifetime CA2065346C (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002485553A Expired - Lifetime CA2485553A1 (fr) 1989-09-05 1990-07-17 Recepteurs .alpha. et .beta. de facteur de necrose tumorale

Country Status (3)

Country Link
AU (1) AU630497B2 (fr)
CA (2) CA2485553A1 (fr)
WO (1) WO1991003553A1 (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
EP0393438B1 (fr) * 1989-04-21 2005-02-16 Amgen Inc. Récepteur du TNF, protéine liant le TNF at ADN codant pour ceux-ci
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
DE59010933D1 (de) 1989-09-12 2003-05-08 Hoffmann La Roche TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
DK0604418T3 (da) * 1991-03-29 1999-06-14 Immunex Corp Isolerede viralproteincytokinantagonister
WO1993006128A1 (fr) * 1991-09-16 1993-04-01 Peptide Technology Limited Peptides antagonistes du facteur de necrose tumorale
DE69230862T2 (de) * 1991-10-15 2000-12-14 Michael F. Mullarkey Rezeptoren zur Behandlung von Entzündungen vom verzögerten Typ
CA2123593C (fr) * 1992-09-15 2000-03-14 Craig A. Smith Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
JPH08508035A (ja) * 1993-03-19 1996-08-27 イミュネックス・コーポレーション 可溶性レセプターと複合化したリガンドを含む医薬組成物
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU724960C (en) 1996-02-09 2002-08-15 Swedish Orphan Biovitrum Ab (Publ) Composition comprising interleukin-1 inhibitor and controlled release polymer
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
DE69738948D1 (de) 1996-12-06 2008-10-09 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
ES2207759T3 (es) 1996-12-06 2004-06-01 Amgen Inc. Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
US20080213778A1 (en) 1998-12-30 2008-09-04 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
ATE299932T1 (de) * 1999-05-10 2005-08-15 Chugai Pharmaceutical Co Ltd Verfahren der zellkultivierung
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ES2382891T3 (es) 2000-05-26 2012-06-14 Immunex Corporation Uso de anticuerpos IL-4R y sus composiciones
SG2011076551A (en) 2001-06-26 2015-08-28 Amgen Inc Antibodies to opgl
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20040136990A1 (en) 2002-07-19 2004-07-15 Abbott Biotechnology Ltd. Treatment of pain using TNFalpha inhibitors
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
TW201337266A (zh) 2005-11-01 2013-09-16 Abbott Biotech Ltd 利用生物標記診斷關節黏連脊椎炎之方法及組合物
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
EP2708242A3 (fr) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
KR101440795B1 (ko) 2006-06-30 2014-09-22 애브비 바이오테크놀로지 리미티드 자동 주사 장치
EA017152B1 (ru) 2006-08-28 2012-10-30 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8092998B2 (en) 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2171451A4 (fr) 2007-06-11 2011-12-07 Abbott Biotech Ltd Procédés de traitement de l'arthrite idiopathique juvénile
WO2010077722A1 (fr) 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Marqueurs sériques prédisant la réponse clinique à des anticorps anti-tnf chez les patients souffrant de spondylarthrite ankylosante
EP2424594A4 (fr) 2009-04-29 2014-12-24 Abbvie Biotechnology Ltd Dispositif d'injection automatique
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CA2781725A1 (fr) 2009-12-16 2011-06-23 Philip Bosch Procedes de traitement de la cystite interstitielle
KR101766936B1 (ko) 2010-01-15 2017-08-09 키린-암젠, 인코포레이티드 항체 제제 및 치료 요법
WO2011097301A2 (fr) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-α
SG184934A1 (en) 2010-04-21 2012-11-29 Abbott Biotech Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
HUE039740T2 (hu) 2010-06-03 2019-01-28 Abbvie Biotechnology Ltd Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
EP2490024A1 (fr) 2010-12-22 2012-08-22 Proteomika, S.L. Procédé pour optimiser le traitement de patients au moyen de médicaments biologiques
ES2637979T3 (es) 2011-01-24 2017-10-18 Abbvie Biotechnology Ltd Dispositivos automáticos de inyección con superficies de agarre sobremoldeadas
US20120233834A1 (en) 2011-03-18 2012-09-20 Abbott Biotechnology Ltd. Systems, devices and methods for assembling automatic injection devices and sub-assemblies thereof
ES2669198T5 (es) 2011-03-29 2021-07-20 Abbvie Inc Despliegue de envolvente mejorado en dispositivos de inyección automáticos
JP6066995B2 (ja) 2011-04-21 2017-01-25 アッヴィ・インコーポレイテッド 装着型自動注射装置
WO2013016220A1 (fr) 2011-07-22 2013-01-31 Amgen Inc. Récepteur a de il-il-17 requis pour biologie il-17c
EP2941243A4 (fr) 2013-01-04 2016-09-14 Massachusetts Inst Technology Liaison de surface de médicaments à base de nanoparticules administrés à des tissus
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
CA2970577A1 (fr) 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3551046B1 (fr) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
EP3554342B1 (fr) 2016-12-14 2024-07-24 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
WO2019246313A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
WO2020010118A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Méthodes de traitement ou de sélection d'un traitement pour un sujet résistant à un inhibiteur de tnf à l'aide d'un antagoniste de nlrp3
WO2020086728A1 (fr) 2018-10-24 2020-04-30 Novartis Inflammasome Research, Inc. Composés et compositions pour traiter des états associés à l'activité d'un nlrp
US20230024859A1 (en) 2018-11-13 2023-01-26 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
US20230025630A1 (en) 2018-11-13 2023-01-26 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
EP3883634A1 (fr) 2018-11-19 2021-09-29 Progenity, Inc. Méthodes et dispositifs pour traiter une maladie à l'aide d'agents biothérapeutiques
WO2020154321A1 (fr) 2019-01-22 2020-07-30 Novartis Inflammasome Research, Inc. Composés et compositions pour traiter des états associés à une activité de nlrp
WO2021002887A1 (fr) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2024054934A1 (fr) 2022-09-07 2024-03-14 Mdx Management Llc Inhibiteurs de shp-1 pour le traitement du cancer
WO2024097804A1 (fr) 2022-11-02 2024-05-10 Mdx Management Llc Combinaison d'un inhibiteur de tyrosine kinase et d'un agent pro-inflammatoire pour le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product

Also Published As

Publication number Publication date
WO1991003553A1 (fr) 1991-03-21
CA2065346A1 (fr) 1991-03-06
AU6178190A (en) 1991-04-08
CA2485553A1 (fr) 1991-03-21
AU630497B2 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
CA2065346C (fr) Recepteurs .alpha. et .beta. de facteur de necrose tumorale
EP0418014B1 (fr) Récepteurs pour le facteur de nécrose de tumeur alpha et beta
US7459528B2 (en) Glycoproteins which bind to TNF
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU670125B2 (en) Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
AU647566B2 (en) Leukemia inhibitory factor receptors
EP0604418B1 (fr) Antagonistes de cytokines a base de proteines virales isolees
US20060275868A1 (en) Fusion proteins comprising tumor necrosis factor receptor
US5264416A (en) Interleukin-7 receptors
FI105099B (fi) Menetelmä biologisesti aktiivisen nisäkkään kasvainkuoliotekijäreseptoriproteiinin valmistamiseksi ja tätä koodittava DNA-sekvenssi
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry